Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Bio    DIM   FR0000053266

News SummaryMost relevantAll newsSector news 

SARTORIUS STED BIO : Sartorius Stedim Biotech and c-LEcta sign sales agreement

05/03/2012 | 07:05am US/Eastern
SSB sells and distributes Serratia marcescens nuclease worldwide | Perfect addition to SSB´s purification product portfolio

Goettingen | Leipzig, Germany, May 3, 2012 - Sartorius Stedim Biotech, a leading international pharma and biotech supplier, and the biotechnology specialist c LEcta, announce the signing of a worldwide sales and distribution agreement for c LEcta's proprietary Serratia marcescens nuclease for biopharmaceutical applications. The German company specializes in the development of customized enzymes and production strains for industrial applications. Based on this agreement, customized endonuclease will now be available under the product name "Denarase" through all regular Sartorius Stedim Biotech sales channels.

Endonucleases are used in various biopharmaceutical production processes, such as in recombinant protein production, to remove nucleic acids, reduce viscosity levels and thus optimize process efficiencies. The company c-LEcta has optimized the production process for Serratia marcescens nuclease using a genetically engineered Bacillus strain to increase enzyme activity yields and remove endotoxins. As a result, this new technology enables the highest purity and quality nuclease to be produced.

"This endonuclease provides outstanding advantages from which our customers will benefit directly, such as cost efficiency and high performance," says Dr. Uwe Gottschalk, Vice President of Purification Technologies at Sartorius Stedim Biotech. "The nuclease is a perfect addition to our current purification product portfolio and supports our strategy as a total solution provider for the biopharmaceutical industry."

Dr. Marc Struhalla, Managing Director of c-LEcta comments, "The technology developed by c-LEcta allows us to provide nuclease to our customers in the highest quality. We are convinced that with Sartorius Stedim Biotech, we have found the right sales and distribution partner for the successful worldwide commercialization of our product."

About c-LEcta GmbH

c-LEcta is a German biotechnology company specializing in the development of customized enzymes and production strains for industrial applications. Patented technologies are employed for discovery and optimization of tailor-made enzymes and microbial strains. c-LEcta's know-how in microbiology and strain engineering allows efficient development of production strains for protein and small-molecule products. Proprietary technologies are used for the identification of new enzymes from biodiversity and for effective enzyme engineering.

distributed by
React to this article
11/17 SARTORIUS STEDIM BIO : Capsules Offer Higher Binding Capacities
10/26 France stocks lower at close of trade; CAC 40 down 0.54%
09/02 GENERAL ELECTRIC : Sartorius Stedim Biotech : and GE Healthcare sign worldwide O..
09/01 SARTORIUS STEDIM BIO : ech and GE Healthcare sign worldwide OEM supply agreement
09/01 SARTORIUS STEDIM BIO : ech : and GE Healthcare sign worldwide OEM supply agreeme..
08/13 SARTORIUS STEDIM BIO : ech : - Improved Membrane Chromatography Performance; Red..
04/20 SARTORIUS STEDIM BIO : ech : Acquires BioOutsource
04/20 SARTORIUS STEDIM BIO : ech launches a new single-use harvesting technology for h..
04/20 SARTORIUS STEDIM BIO : ech : acquires UK-based CRO, BioOutsource; Takeover expan..
04/20 SARTORIUS STEDIM BIO : ech off to a dynamic start into 2015 (First quarter Figur..
News chart
Full-screen chart
Income Statement Evolution
More Financials